The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 16, 2023

Filed:

Sep. 13, 2019
Applicant:

Modernatx, Inc., Cambridge, MA (US);

Inventors:

Paolo Martini, Cambridge, MA (US);

Stephen G. Hoge, Brookline, MA (US);

Kerry Benenato, Sudbury, MA (US);

Vladimir Presnyak, Manchester, NH (US);

Iain Mcfadyen, Arlington, MA (US);

Ellalahewage Sathyajith Kumarasinghe, Harvard, MA (US);

Xuling Zhu, Cambridge, MA (US);

Lin Tung Guey, Cambridge, MA (US);

Staci Sabnis, Cambridge, MA (US);

Assignee:

ModernaTX, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/67 (2006.01); A61K 9/51 (2006.01); C12N 9/40 (2006.01); A61P 3/00 (2006.01); A61K 38/47 (2006.01);
U.S. Cl.
CPC ...
C12N 15/67 (2013.01); A61K 9/5123 (2013.01); A61K 38/47 (2013.01); A61P 3/00 (2018.01); C12N 9/2465 (2013.01); C12Y 302/01022 (2013.01); A61K 48/00 (2013.01);
Abstract

The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.


Find Patent Forward Citations

Loading…